[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644203":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":31,"eligibilityCriteria":32,"healthyVolunteers":27,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":10,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":10},{"fullName":5,"class":6},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"GROUP 1 - AB+Serenoa repens",null,"PATIENTS TREATED WITH AB+Serenoa repens",{"label":13,"type":10,"description":14,"interventionNames":10},"GROUP 2 - AB+antimuscarinics","PATIENTS TREATED WITH AB+antimuscarinics",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"LUCA BOERI, MD, PHD","CONTACT","+390255034501","LUCA.BOERI@POLICLINICO.MI.IT",{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Luca Boeri","MD, PHD","100644203","efficacy-and-tolerability-of-treatment-with-alfalitic-plus-serenoa-repens-compared-to-alfalitic-plus-antimuscarinic-for-moderate-severe-lower-urinary-tract-symptoms-100644203",false,"NCT07665749","Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Lower Urinary Tract Symptoms","Efficacy and Tolerability of Treatment With Alfalitic Plus Serenoa Repens Compared to Alfalitic Plus Antimuscarinic for Moderate-severe Mixed Lower Urinary Tract Symptoms: Results of a Cross-sectional Clinical Study","FINAL","Inclusion Criteria:\n\n* Age 40-80 inclusive\n* Male\n* With moderate-to-severe LUTS from BPH according to IPSS score\n* Placed on AB+Serenoa repens or AB+antimuscarinics for 6 months\n\nExclusion Criteria:\n\n* Prostate or bladder cancer\n* History of neurogenic bladder\n* Urinary tract abnormalities (including urethral strictures)","MALE","40 Years","80 Years",{"count":37,"type":38},50,"ESTIMATED","OBSERVATIONAL","The study aims to investigate, through the International Prostatic Symptoms Score (IPSS) questionnaire, the non-inferiority of the therapy with the alpha-blockers+Serenoa repens combination compared to the alpha-blockers+antimuscarinic combination on storage lower urinary tract syndrome (LUTS) in patients with moderate-severe symptomatic benign prostatic hyperplasia (BPH).",[42],"Benign Prostate Hypertrophy(BPH)",[44,45],"BPH","LUTS","NOT_YET_RECRUITING","2026-06-24",{"date":49,"type":50},"2026-06-26","ACTUAL",{"date":52,"type":38},"2026-06-01",{"date":54,"type":38},"2026-11-01",{"name":5,"class":6}]